After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
A biliary tract cancer trial hits on response rate, but survival data will be key.
AACR approaches, along with ASCO abstract titles.
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
